Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

Neurology

Volumn 84, Issue 11, 2015, Pages 1145-1152

  Miller, David H ^a,b   Fox, Robert J ^c   Phillips, J Theodore ^d   Hutchinson, Michael ^e   Havrdova, Eva ^f   Kita, Mariko ^g   Wheeler Kingshott, Claudia A M ^a,b   Tozer, Daniel J ^a,b   MacManus, David G ^a,b   Yousry, Tarek A ^a,b   Goodsell, Mary ^h   Yang, Minhua ⁱ   Zhang, Ray ⁱ   Viglietta, Vissia ⁱ   Dawson, Katherine T ⁱ  

^a University College London   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^f CHARLES UNIVERSITY   (Czech Republic)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h CircleScience   (United Kingdom)

ⁱ BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; PLACEBO; DELAYED RELEASE FORMULATION; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN SIZE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TISSUE STRUCTURE; TREATMENT DURATION; YOUNG ADULT; ADMINISTRATION AND DOSAGE; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; INTERNATIONAL COOPERATION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; TRENDS;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DIMETHYL FUMARATE; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925340335     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001360     Document Type: Article

References (30)

1. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208:2291-2303.
2. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-692.
3. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002;168:4781-4787.
4. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the Nrf2 pathway. J Pharmacol Exp Ther 2012;341:274-284.
5. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
6. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
7. US Food and Drug Administration. TECFIDERATM Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204063lbl.pdf. Accessed April 2, 2013.
8. Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 2011;68:1514-1520.
9. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407-415.
10. Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology 2013;80:246-252.
11. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001;47:45-50.
12. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/. Accessed November 22, 2010.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald criteria." Ann Neurol 2005;58:840-846.
14. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
15. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969.
16. Morgan CJ, Ranjan A, Aban IB, et al. The magnetic resonance imaging "rule of five": predicting the occurrence of relapse. Mult Scler 2013;19:1760-1764.
17. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
18. Barkhof F. Assessing treatment effects on axonal loss: evidence from MRI monitored clinical trials. J Neurol 2004;251(suppl 4):IV6-IV12.
19. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet 2008;372:1463-1472.
20. Kappos L, Gold R, Miller DH, et al. Effect of BG-12 on contrast-enhancing lesions in patients with relapsingremitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 2012;18:314-321.
21. Macmanus DG, Miller DH, Kappos L, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2011;258:449-456.
22. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-1009.
23. Comi G, Cook SD, Giovannoni G, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol 2013;260:1136-1146.
24. Radue EW, O'Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012;69:1259-1269.
25. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013;19:1310-1319.
26. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-107.
27. Arnold D, Gold R, Kappos L, et al. Effects of BG-12 on magnetization transfer ratio in whole brain and normal-appearing brain tissue: findings from the DEFINE study. Neurology 2012;78:S11.004.
28. Arnold D, Gold R, Kappos L, et al. Effect of BG-12 on brain atrophy and lesions volume: MRI results from the DEFINE study during first and second year of treatment. Neurology 2012;78:S11.003.
29. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013;19:1074-1083.
30. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001;124:1803-1812.